Table 1.
Schedule of assessments.
| Assessment | Timepoint | ||||||||||
|
|
Enrollment and baselinea | Treatment periodb | Follow-upc | ||||||||
|
|
T0 | T1-9; T11-19; T21-29 | T10; T20 | T30 | T60 | ||||||
| Prerandomization | |||||||||||
|
|
Informed consent | ✓d | —e | — | — | — | |||||
|
|
Screening of inclusion and exclusion criteria | ✓ | — | — | — | — | |||||
|
|
History and physical exam | ✓ | — | — | — | — | |||||
|
|
EHIf | ✓ | — | — | — | — | |||||
|
|
MINIg (audio recorded) | ✓ | — | — | — | — | |||||
|
|
MGH-ATRQh | ✓ | — | — | — | — | |||||
|
|
MADRSi (audio recorded) | ✓ | — | — | ✓ | — | |||||
| Postrandomization | |||||||||||
|
|
MADRS (not recorded) | — | — | ✓ | — | ✓ | |||||
|
|
QIDS-SR-16j | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
WHODASk 2.0 | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
SCIPl | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
YMRSm | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
tDCS-AEQn | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
FIBSERo | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
PRISEp | ✓ | — | ✓ | ✓ | ✓ | |||||
|
|
Auditory lexical decision task | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
aT0: baseline session.
bT1-30: treatment sessions 1 to 30.
cT60: follow-up one session, one month after trial completion.
dAssessment conducted.
eAssessment not conducted.
fEHI: Edinburgh Handedness Inventory.
gMINI: Mini International Neuropsychiatric Interview.
hMGH-ATRQ: Massachusetts General Hospital Antidepressant Treatment History Questionnaire.
iMADRS: Montgomery-Åsberg Depression Rating Scale.
jQIDS-SR-16: Quick Inventory of Depressive Symptomatology.
kWHODAS: World Health Organization Disability Assessment Schedule.
lSCIP: Screen for Cognitive Impairment in Psychiatry.
mYMRS: Young Mania Rating Scale.
ntDCS-AEQ: Transcranial Direct Current Stimulation Adverse Events Questionnaire.
oFIBSER: Frequency, Intensity, and Burden of Side Effects Rating Scale.
pPRISE: Patient-Rated Inventory of Side Effects Scale.